Pharmaceuticals & Therapeutics

Facing a challenging EV market, Aspen Aerogels looks to the Roth Conference to showcase its long-term growth strategy and advanced aerogel technology.

With promising clinical data for its lead drug silevertinib and a strong new financial position, Black Diamond Therapeutics charts a dual course for two deadly cancers.

JAMP Pharma Group introduces a generic version of a key prostate cancer drug, aiming to reduce healthcare costs and enhance patient support in Canada.

A new alliance aims to overhaul Alzheimer's research, demanding a precision approach for the 65% of patients carrying the high-risk APOE4 gene.

With over half of pets overweight, a renewed partnership is fighting the silent epidemic through science, nutrition, and accessible veterinary care.

San Diego biotech elevates key execs as it advances its inflammation pipeline, backed by Sanofi and Lilly, into a competitive and high-stakes market.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

The body contouring firm faces investor unease over a delayed annual report, even as it points to a sales rebound from a new marketing push.

The firm continues its monthly dividend while positioning its funds to capitalize on global instability, doubling down on defense, gold, and energy sectors.

Groundbreaking Hong Kong research uncovers why the common ‘Asian Flush’ gene dramatically worsens heart attack outcomes, paving the way for new treatments.

As employers grapple with soaring obesity drug costs, a new partnership aims to offer predictable pricing and comprehensive care. Here's how it works.

Aditxt's $36M acquisition of Ignite Proteomics aims to upend cancer therapy by analyzing protein activity, a high-stakes bet for the struggling innovator.

With a $35 million boost from RA Capital, Equillium extends its cash runway to 2029, fueling the clinical development of its promising oral UC therapy, EQ504.

Genenta's rebrand to Saentra Forge signals a major shift into Italian national security, as its CEO gains a key government-backed diplomatic post.

Colgate-Palmolive signals confidence with its 63rd annual dividend hike and appoints Bristol Myers Squibb's CEO to its board, a strategic health pivot.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

With new clinical data and a clear path to Phase 2 trials, Gain Therapeutics' GT-02287 offers hope for a disease-modifying therapy for Parkinson's.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

After a massive divestiture and balance sheet overhaul, Elutia is all-in on its next-gen biomatrix, NXT-41x, to disrupt the $1.5B breast surgery market.

The Personalized Health Association launches to modernize U.S. policy, sparking debate over innovation, patient safety, and the future of tailored care.